-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

Benzinga·09/23/2026 11:38:01
Diffusion vocale
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $50 to $57.